NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

MUNICH--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE ... to enhance the long-term value of their products. DSE has agreed to pay Esperion ...

At the same time, and also based on the Destiny-Breast06 trial, Daiichi announced that the European Medicines ... for Medicinal Products for Human Use," Daiichi Sankyo explained.

Daiichi Sankyo – which licenses rights to Nexletol in some markets – disagrees. It is on the hook for the milestone payment once the CLEAR results are added into the drug’s label in Europe ...

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care ...

Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...

and the 2024 European Society for Medical Oncology (#ESMO24). Data at WCLC and ESMO showcasing Daiichi Sankyo’s progress towards its goal of creating new standards of care for patients with ...

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the ...

Daiichi Sankyo Co Ltd on Monday announced positive updates for Enhertu, with the cancer drug receiving support from U ... Subscribe now to see this Premium News article from Alliance News ...

2 Daiichi Sankyo committed to ETNA-AF, which combines data from distinct non-interventional studies in Europe, East Asia, and Japan in a single database, to delve deeper into the global burden of CVD.